US, Nov. 18 -- A blood biomarker for Alzheimer's disease may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or 10 years, according to a new Mayo Clinic study in JAMA Neurology.

The approach combines a blood measure of phosphorylated Tau 217 (p-tau217), a biomarker associated with Alzheimer's disease, with age, sex and genetic risk to estimate a person's future risk of cognitive impairment. Higher p-tau217 levels and older age were associated with greater risk.

"The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid patholog...